Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre randomised controlled study. by Ghert, Michelle et al.
UC Davis
UC Davis Previously Published Works
Title
Prophylactic antibiotic regimens in tumour surgery (PARITY): protocol for a multicentre 
randomised controlled study.
Permalink
https://escholarship.org/uc/item/24r7s364
Journal
BMJ open, 2(6)
ISSN
2044-6055
Authors
Ghert, Michelle
Deheshi, Benjamin
Holt, Ginger
et al.
Publication Date
2012
DOI
10.1136/bmjopen-2012-002197
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Prophylactic antibiotic regimens
in tumour surgery (PARITY): protocol
for a multicentre randomised controlled
study
Michelle Ghert,1 Benjamin Deheshi,1 Ginger Holt,2 R Lor Randall,3
Peter Ferguson,4 Jay Wunder,4 Robert Turcotte,5 Joel Werier,6 Paul Clarkson,7
Timothy Damron,8 Joseph Benevenia,9 Megan Anderson,10 Mark Gebhardt,10
Marc Isler,11 Sophie Mottard,11 John Healey,12 Nathan Evaniew,1
Antonella Racano,1 Sheila Sprague,1 Marilyn Swinton,1 Dianne Bryant,1
Lehana Thabane,1 Gordon Guyatt,1 Mohit Bhandari,1 The PARITY Investigators
To cite: Ghert M, Deheshi B,
Holt G, et al. Prophylactic
antibiotic regimens in tumour
surgery (PARITY): protocol
for a multicentre randomised
controlled study. BMJ Open
2012;2:e002197.
doi:10.1136/bmjopen-2012-
002197
▸ Prepublication history and
additional material for this
paper are available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2012-002197).
Received 10 October 2012
Accepted 19 October 2012
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
For numbered affiliations see
end of article
Correspondence to
Dr Michelle Ghert;
michelle.ghert@jcc.hhsc.ca
ABSTRACT
Introduction: Limb salvage with endoprosthetic
reconstruction is the standard of care for the
management of lower-extremity bone tumours in
skeletally mature patients. The risk of deep
postoperative infection in these procedures is high and
the outcomes can be devastating. The most effective
prophylactic antibiotic regimen remains unknown, and
current clinical practice is highly varied. This trial will
evaluate the effect of varying postoperative prophylactic
antibiotic regimens on the incidence of deep infection
following surgical excision and endoprosthetic
reconstruction of lower-extremity bone tumours.
Methods and analysis: This is a multicentre,
blinded, randomised controlled trial, using a parallel
two-arm design. 920 patients 15 years of age or older
from 12 tertiary care centres across Canada and the
USA who are undergoing surgical excision and
endoprosthetic reconstruction of a primary bone
tumour will receive either short (24 h) or long (5 days)
duration postoperative antibiotics. Exclusion criteria
include prior surgery or infection within the planned
operative field, known colonisation with methicillin-
resistant Staphylococcus aureus or vancomycin-
resistant Enterococcus at enrolment, or allergy to the
study antibiotics. The primary outcome will be rates of
deep postoperative infections in each arm. Secondary
outcomes will include type and frequency of antibiotic-
related adverse events, patient functional outcomes and
quality-of-life scores, reoperation and mortality.
Randomisation will be blocked, with block sizes known
only to the methods centre responsible for
randomisation, and stratified by location of tumour and
study centre. Patients, care givers and a Central
Adjudication Committee will be blinded to treatment
allocation. The analysis to compare groups will be
performed using Cox regression and log-rank tests to
compare survival functions at α=0.05.
Ethics and dissemination: This study has ethics
approval from the McMaster University/Hamilton Health
Sciences Research Ethics Board (REB# 12-009).
ARTICLE SUMMARY
Article focus
▪ Prophylactic antibiotic regimens in tumour
surgery (PARITY) is a multicentre, blinded, ran-
domised controlled trial, using a parallel two-arm
design to investigate whether long-duration
(5 days) postoperative prophylactic antibiotics
will decrease the rate of infection compared to
short duration (24 h) among patients undergoing
surgical excision and endoprosthetic reconstruc-
tion of lower-extremity primary bone tumours.
Key messages
▪ The immediate goal of PARITY is to provide
high-quality evidence that can be used in the
development of clinical guidelines for antibiotic
prophylaxis following lower-extremity tumour
excision and endoprosthetic reconstruction.
▪ Whereas sarcomas of the long bones are very
rare tumours, multicentre international collabor-
ation on a large scale is necessary to adequately
power any high-quality trials in this field.
▪ PARITY will mark the first such undertaking, and
the rigorous design, organisation and execution
of this trial will set a high standard.
Strengths and limitations of this study
▪ PARITY will establish a successful network of
collaboration from which further high-quality
trials in Orthopaedic Oncology will follow.
▪ The rationale supporting the study design
includes demonstrated clinical uncertainly, lack
of high-quality evidence and documented strong
investigator support.
▪ The methodology is supported by tremendous
expertise and experience in running large inter-
national surgical trials of the Methods Center at the
McMaster Center for Evidence-Based Orthopaedics.
▪ This is a protocol paper; this trial is underway,
but has not been completed.
Ghert M, Deheshi B, Holt G, et al. BMJ Open 2012;2:e002197. doi:10.1136/bmjopen-2012-002197 1
Open Access Protocol
Successful completion will significantly impact on clinical practice
and enhance patients’ lives. More broadly, this trial will develop a
network of collaboration from which further high-quality trials in
Orthopaedic Oncology will follow.
BACKGROUND
Magnitude of the problem
Sarcomas, or malignancies of connective tissue, are a
rare form of cancer. These tumours may arise in the
long bones of the extremities, and when doing so they
often affect adolescents and young adults. Long-bone
sarcomas were historically managed with amputations,
but the current standard is limb salvage surgery. Limb
salvage involves wide tumour resection followed by func-
tional reconstruction. With the aid of modern imaging
techniques and chemotherapeutic regimens, limb
salvage is possible in 95% of patients.
The most common type of functional reconstruction
involves the use of tumour endoprostheses. Tumour
endoprostheses are modular metallic and polyethylene
implants that replace surgically resected bones and
joints. Due to the complexity and length of these proce-
dures, as well as the immunocompromised nature of
patients treated with chemotherapy, the risk for deep
postoperative infection is high and the outcomes can be
devastating.1 2 Deep infections require staged endopros-
thetic revision surgery and long-term intravenous anti-
biotic therapy.3 Even following this management,
subsequent repeat infection and ultimate amputation
are not uncommon.1 4 5 Patients’ function and quality of
life are dramatically impacted, as are healthcare costs.6
Published guidelines for postoperative antibiotic
prophylaxis following many standard elective surgical
procedures dictate that prophylactic antibiotics be dis-
continued after 24 h.7 However, the most effective
prophylactic antibiotic regimen to prevent deep post-
operative infection following surgical excision and endo-
prosthetic reconstruction of lower-extremity bone
tumours remains unknown. Current clinical practice is
highly varied, particularly with respect to antibiotic dur-
ation. Strategies to optimise the prevention of these
infections while mitigating healthcare costs are needed.
Best evidence for infection rates
We performed a systematic review to determine reported
infection rate outcomes following the treatment of
primary long bone tumours (malignant and benign
aggressive) by surgical excision and endoprosthetic
reconstruction. A literature search of Medline, EMBASE
and the Cochrane database was conducted, and the pro-
ceedings of past American Society for Clinical Oncology
Annual Meetings were also searched. The search was
limited to articles published in English, and no restric-
tions were placed on dates of publication.
This search generated 3889 titles. In order to minim-
ise bias and ensure that studies were not overlooked, all
titles and abstracts were screened by two independent
reviewers. Those papers reporting outcomes of endo-
prosthetic reconstruction in the treatment of malignant
or benign aggressive long bone tumours were selected
for review. Studies reporting on the use of allografts or
allograft-prosthesis composites were excluded. Studies
investigating soft-tissue sarcomas, metastatic lesions,
recurrent lesions or lesions that had received prior surgi-
cal treatment were excluded. The reported infection
rates were extracted from the remaining papers and
compared. Both reviewers performed data extraction
and assessment of data quality independently, and differ-
ences were reconciled by mutual agreement or an inde-
pendent third party.
Of the 3889 titles, there were 48 eligible studies
(table 1). The deep-infection rates ranged from 0% to
22.2%, with a weighted mean of 9.5% (95% CI 8.1% to
11.0%). Duration of antibiotic prophylaxis was reported
inconsistently, but ranged from ‘intraoperative dosing
only’ to ‘greater than 72 h’.
Complications of antibiotic overuse
Antibiotic resistance is an issue of steadily increasing
clinical importance. Our systematic review demonstrated
that the most common reported pathogen to infect
endoprosthetic reconstructions after surgical excision of
long-bone tumours is Staphylococcus aureus. Although
methicillin-sensitive S aureus remains overwhelmingly sus-
ceptible to Ancef (cefazolin),51 the prevelance of
methicillin-resistant S aureus (MRSA) is rising. In Canada,
the incidence of MRSA as a proportion of all S aureus
has increased from 1% in 1995 to 27% in 2008.51
Zhanel et al 51 found that 68.8% of all MRSA isolates
were healthcare-associated strains [HA-MRSA], while
27% were community-associated [CA-MRSA]). In 2009,
all HA-MRSA and CA-MRSA isolates were susceptible to
vancomycin, with varying sensitivities to other agents.51
Two main factors in the development of antibiotic
resistance are antibiotic misuse and overuse.52 Antibiotic
misuse is the selection of antimicrobial agents with
inappropriately broad spectrums of efficacy, and anti-
biotic overuse is an inappropriately excessive frequency
or duration of antibiotic prescription. Whereas increas-
ing antibiotic resistance has the potential to significantly
impair management of patients with infected endo-
prostheses, an evidence-based approach to antibiotic use
is critical.
Other important complications of antibiotic overuse
include the development of Clostridium difficile-associated
colitis and life-threatening toxic megacolon, opportunis-
tic fungal infections, indwelling-catheter related sepsis
and seizures.53–57
Lack of consensus in antibiotic regimens and global
interest in randomised controlled trial
We conducted a survey addressing the practices of
Orthopaedic Oncologists registered with the
Musculoskeletal Tumor Society (MSTS) and the Canadian
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Orthopaedic Oncology Society.58 From this survey, we con-
cluded that there are currently no guidelines for the pre-
scription of prophylactic antibiotics in musculoskeletal
tumour surgery, and that current opinion and practice are
highly varied. Of the 97 surgeons who received the ques-
tionnaire, 72 responded (75% response rate (95% CI
65.5% to 82.5%)). Almost all respondents agreed that
prophylactic antibiotic regimens were important in redu-
cing the risk of postoperative deep infection, but there was
considerable variety in antibiotic choice and duration.
Seventy-three per cent (95% CI 61% to 82%) of respon-
dents reported prescribing only a first generation cephalo-
sporin, while 11% reported prescribing a first-generation
cephalosporin in combination with an aminoglycoside
and/or vancomycin. Thirty-six per cent (95% CI 25% to
48%) discontinue antibiotics after 24 h, compared with
41% (95% CI 30% to 53%) who continue antibiotics until
the suction drain is removed.
When asked if they would change their practice if a
large randomised controlled trial (RCT) showed clear
benefit for an antibiotic regimen different from their own
current practice, 90% (95% CI 81% to 95%) of respon-
dents reported they would. Further, 87% (95% CI 77% to
93%) expressed an interest to participate in such a trial.
Summary: rationale for a definitive RCT
Deep infections following surgical excision and endo-
prosthetic reconstruction of lower-extremity bone
tumours are devastating complications. In combination
with the existing literature, our earlier work has demon-
strated: (1) high infection rate outcomes following the
treatment of primary long bone tumours by surgical exci-
sion and endoprosthetic reconstruction; (2) a lack of
high-level RCT evidence to guide the prescription of
prophylactic antibiotic regimens; (3) highly variable
opinion and practice regarding prophylactic antibiotic
regimens among Orthopaedic Oncologists and (4) exten-
sive investigator support for a definitive large RCT.59
These findings provide a strong rationale for undertaking
a definitive RCT. The direct potential clinical implica-
tions of this work include both fewer endoprosthetic
infections and fewer antibiotic-related complications.
STUDY DESIGN
Overview of study design
Prophylactic antibiotic regimens in tumour surgery
(PARITY) is a multicentre, blinded, RCT, using a parallel
two-arm design to investigate whether long duration
(5 days) postoperative prophylactic antibiotics will
decrease the rate of infection compared with short dur-
ation (24 h) among patients undergoing surgical excision
and endoprosthetic reconstruction of lower-extremity
primary bone tumours. Randomisation will be stratified by
study centre and tumour location (femur vs tibia). Patient
enrolment will occur over approximately 1 year and
enrolled patients will be followed for 1-year postoperatively.
Infection rates will be assessed within 12 months after
initial surgery across both study arms. Patient function and
quality of life will be assessed preoperatively and at
3-month, 6-month and 1-year follow-up visits. Trial
conduct procedure is shown in figure 1. This trial is regis-
tered [NCT01479283] and has received ethics approval
from the McMaster University/Hamilton Health Sciences
Research Ethics Board (REB# 12-009).
Table 1 Deep infection rates reported by systematic
review
Study Year Number Infection rate (%)
Lee et al8 1990 17 0.0
Roberts et al9 1991 133 7.5
Horowitz et al10 1991 12 25.0
Eckardt et al11 1991 68 1.5
Shih et al12 1993 61 6.6
Morris et al13 1995 31 3.2
Malawer et al14 1995 51 19.6
Zehr et al15 1996 17 5.9
Abudu et al16 1996 16 0.0
Abudu et al17 1999 5 20.0
Lee et al18 1999 6 20.0
Grimer et al19 1999 151 18.5
Kawai et al20 1999 32 6.3
Kabukcuoglu et al21 1999 54 1.9
Natarajan et al22 2000 6 16.7
Ilyas et al23 2000 15 13.3
Ilyas et al24 2001 48 8.3
Donati et al25 2001 25 4.2
Wunder et al26 2001 64 6.3
Griffin et al27 2005 99 10.1
Sokolov et al28 2002 30 13.3
Ilyas et al29 2002 15 6.7
Bickels et al30 2002 110 5.5
Antract et al31 2002 9 22.2
Natarajan et al32 2005 246 6.9
Jeys et al33 2005 1036 11.9
Sharma et al34 2006 77 7.8
Farid et al35 2006 52 3.8
Orlic et al36 2006 82 4.9
Gosheger et al37 2006 199 13.6
Sharma et al38 2007 112 9.8
Myers et al39 2007 194 19.6
Sim et al40 2007 50 12.00
Finstein et al41 2007 62 4.80
Myers et al39 2007 335 9.6
Akahane et al6 2007 11 9.1
Gitelis et al42 2008 80 2.5
Guo et al43 2008 104 6.7
Jeys et al44 2008 530 12.8
Sewell et al45 2009 22 0.0
Natarajan et al32 2009 17 11.8
Shekkeris et al46 2009 6 16.7
Lee et al18 2009 256 9.8
Morii et al2 2010 82 17.1
Hanna et al47 2010 22 4.5
Hardes et al48 2010 125 12.8
Li et al49 2011 50 8.0
Sewell et al50 2011 14 7.1
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Primary research question
In patients with a diagnosis of a primary malignant or
benign aggressive bone tumour of the lower extremity,
do long-duration prophylactic antibiotics following
surgical excision and endoprosthetic reconstruction of
lower-extremity bone tumours, in comparison with short-
duration prophylactic antibiotics, lead to decreased rates
of postoperative deep infections over 12 months?
Secondary research questions
In patients with a diagnosis of a primary malignant or
benign aggressive bone tumour of the lower extremity,
do long-duration prophylactic antibiotics following
surgical excision and endoprosthetic reconstruction of
lower-extremity bone tumours, in comparison with short-
duration prophylactic antibiotics, lead to:
1. Any differences in frequency or type of
antibiotic-related adverse over 12 months?
2. Any differences in patient functional outcome and
quality-of-life scores over 12 months?
3. Any differences in occurrence of adverse events, serious
adverse events, infections other than deep-surgical site
infections, complications of wound healing, tumour
recurrence or metastases, reoperation or mortality
between long and short-duration prophylactic antibio-
tics over 12 months?
Hypothesis
As a primary outcome, there will be significantly fewer
deep postoperative infections and no significant increase
in frequency or severity of antibiotic-related complica-
tions associated with long duration in comparison with
short-duration prophylactic antibiotics. As secondary out-
comes, we expect no differences in patient functional
outcome scores, quality-of-life scores, adverse events,
serious adverse events, infections other than deep-
Figure 1 Trial Conduct Procedure. *Follow-Up Forms include adverse events (AE)s, serious adverse events (SAE)s, infections,
reoperations, protocol deviations and wound healing problems and other appropriate forms.
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surgical site infections, complications of wound healing,
tumour recurrence or metastases, reoperation or mortal-
ity between long and short-duration prophylactic antibio-
tics. This study is powered to address the primary
outcome and will also be powered to identify minimally
important differences in functional outcomes.
Eligibility criteria
Inclusion criteria
Men and women 15 years of age or older who meet all
the following criteria will be included in the study:
1. Diagnosis of a primary malignant or benign aggres-
sive bone tumour of the lower extremity;
2. Planned treatment of surgical excision and endopros-
thetic reconstruction;
3. Provision of informed consent.
Exclusion criteria
Patients who meet any one or more of the following cri-
teria will be excluded from the study:
1. Known skin colonisation with MRSA, or vancomycin-
resistant Enterococcus at the time of enrolment;
2. Allergy to Ancef (cefazolin) or penicillin, consisting
of anaphylaxis or angioedema;
3. Prior surgery within the planned operative field,
excluding a biopsy;
4. Prior infection within the planned operative field.
Recruitment and screening
Each clinical site will have a locally responsible investiga-
tor that will oversee local administration of the trial. The
treating physicians, investigators, study coordinators
and/or their delegates at each site will identify poten-
tially eligible patients upon presentation with a lower-
extremity bone tumour requiring surgical excision and
endoprosthetic reconstruction. All potentially eligible
patients will be screened and documented as: (1) eli-
gible and included, (2) eligible and missed or (3)
excluded. The study coordinator or designee will obtain
informed consent for participation in the study using
local IRB/REB approved Informed Consent forms.
Consent will be obtained at the final preoperative visit
1–2 weeks prior to the anticipated date of the surgery
and at the same time that consent is obtained for the
procedure. Baseline characteristics forms and preopera-
tive functional outcome and quality-of-life questionnaires
will be completed at the time of consent.
Allocation of patients to study groups
Patients will be randomised to either short-duration or
long-duration prophylactic antibiotics only after patient
eligibility is established and patient consent is obtained.
Actual randomisation will occur during surgery, prior to
case completion and will be carried out by the pharmacy
technician using an internet-based randomisation system
that ensures concealment. The pharmacy will be noti-
fied of upcoming study participants both at the time of
consent and on the morning of surgery. Randomisation
will be blocked, with block sizes known only to the
methods centre responsible for randomisation. Patients
will be the unit of randomisation. Randomisation will be
stratified for: (1) location of tumour (femur vs tibia)
and (2) study centre.
Study interventions
Surgical excision and endoprosthetic reconstruction will
be performed according to the standard practice of the
participating surgeons. This typically involves a wide
extensile surgical exposure, isolation and protection of
major neurovascular structures, resection of the segment
of bone affected by tumour with a 2–3 cm bone margin,
and a soft-tissue margin dictated by the amount of avail-
able tissue that can be safely resected from both onco-
logical and functional standpoints. Endoprostheses may
be implanted with either press-fit or cemented techni-
ques. Soft-tissue reconstruction may or not may not
require tissue transfer based on the original extent of
the tumour and required soft-tissue excision to establish
wide oncological margins.
Tumor Characteristics Forms, Surgical Report Forms,
Peri-operative Forms and Antibiotics Logs will be com-
pleted at the time of surgery. Patients will be assessed for
adverse events and protocol deviations in the periopera-
tive period. All patients will receive 2 g of intravenous
Ancef preoperatively and every 3–4 h intraoperatively.
Short-duration antibiotics
Patients randomised to the short-duration regimen will
receive 2 g of intravenous Ancef postoperatively every
8 h for 24 h, followed by intravenous ‘sham’ antibiotics
(normal saline) for an additional 4 days.
Long-duration antibiotics
Patients randomised to the long-duration regimen will
receive 2 g of intravenous Ancef postoperatively every
8 h over a 5-day period (maximum), or until hospital
discharge if acute care stay is less than 5 days.
Blinding
All antibiotic bags will be identically shrouded. No other
antibiotics will be administered for infection prophy-
laxis. Patients, surgeons, nurses, research personnel,
data analysts and the Central Adjudication Committee
(CAC) will be blinded to the antibiotic duration. The
pharmacy technician preparing and shrouding the solu-
tions will not be blinded.
Outcome measures
Primary cutcome
The primary study outcome will be rates of deep post-
operative infections in each of the study arms. The CDC
definition of a deep surgical site infection (below) will
be employed (http://www.cdc.gov/nhsn/PDFs/
pscManual/9pscSSIcurrent.pdf). Patients will be moni-
tored regularly for this outcome by their treating physi-
cians at 2 and 6 weeks, and 3, 6 and 9 months, and
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1-year postoperatively. If deep infection does occur, the
causative organism will be determined and documented.
The CDC criteria we will use define infection as
follows: The infection occurs within 30 days after the
operative procedure or within 1 year if an implant is in
place and the infection appears to be related to the
operative procedure. The infection may involve any part
of the body, excluding the skin incision, fascia or muscle
layers that is opened or manipulated during the opera-
tive procedure. The patient must have at least 1 of the
following:
1. Purulent drainage from a drain that is placed
through a stab wound into the organ/space;
2. Organisms isolated from an aseptically obtained
culture of fluid or tissue in the organ/space;
3. An abscess or other evidence of infection involving
the organ/space that is found on direct examination,
during reoperation or by histopathological or radio-
logical examination;
4. Diagnosis of an organ/space SSI by a surgeon or
attending physician.
Secondary outcomes
The secondary study outcomes include type and fre-
quency of antibiotic-related adverse events, patient func-
tional outcome scores, and patient quality-of-life scores.
We will also evaluate for occurrence of adverse events,
serious adverse events, infections other than deep-
surgical site infections, complications of wound healing,
incidence of tumour recurrence or metastasis, reopera-
tion and mortality. As noted in figure 1, the MSTS func-
tional score (clinician administered), the Toronto
Extremity Salvage Score (TESS) (patient administered)
and the Short Musculoskeletal Functional Assessment
(SMFA) questionnaires will be used to assess functional
outcomes prior to surgery, and at the 3-month, 6-month
and 1-year follow-up visits. The MSTS and TESS instru-
ments are based on validated, well-accepted functional
scoring systems in Orthopaedic Oncology publica-
tions.59–61 The Short Musculoskeletal Function
Assessment questionnaire is a reliable, responsive, vali-
dated instrument that evaluates general health status in
patients with musculoskeletal disorders.62 63
Adjudication of outcomes
A blinded CAC will adjudicate all occurrences of
deep-surgical site infection. The committee will also
adjudicate all occurrences of an antibiotic-related com-
plication, occurrence of an infection other than a
deep-surgical site infection, occurrence of an adverse
event or serious adverse event, complications of wound
healing, recurrence, metastasis, reoperation, mortality or
doubt of eligibility. The CAC will be comprised of three
Orthopaedic Surgeons and one Infectious Diseases spe-
cialist and the Global Adjudicator web-based platform
will be used.64
Patient follow-up
Patients will be assessed at the time of regular follow-up
by their treating physician at 2 and 6 weeks, and 3, 6
and 9 months and 1-year postoperatively. Patients will be
assessed for infections (surgical site and other),
antibiotic-related complications, adverse events, serious
adverse events, complications of wound healing, oncolo-
gic outcomes such as local recurrence and metastasis,
reoperation, mortality and protocol deviations.
Accompanying forms will be completed as scheduled on
figure 1. A Missed Follow-Up Form will be completed if
a patient misses a follow-up visit. An Early Withdrawal
Form will be completed only if a patient withdraws their
consent.
Maximisation of follow-up
Given the malignant potential and patient concern asso-
ciated with long bone sarcomas, we anticipate only
minimal losses to follow-up in our Orthopaedic
Oncology population. Nonetheless, the following proce-
dures will be implemented to minimise losses (1) exclu-
sion of individuals who are likely to present difficulty
with follow-up; (2) at the baseline assessment, each
patient shall provide their own address and phone
number, the name and address of their primary care
physician, and the name, address and phone number of
three people at different addresses with whom the
patient did not live who were likely to be aware of the
patient’s whereabouts; (3) patients will receive remin-
ders for upcoming clinic visits from the study coordina-
tors; (4) follow-up schedules will coincide with normal
postoperative clinic visits; (5) if a patient refuses to
return for a follow-up assessment, his/her status with
regard to the primary and secondary outcomes will be
assessed as much as possible by telephone contact with
the patient, alternate contact or their family physician.65
Minimisation of crossovers
Crossovers are extremely unlikely between the short-
duration and long-duration antibiotic regimens given
that patients will be blinded and acute infections are
unlikely to be recognised in the first 5 days after surgery.
Any patients who do crossover will be analysed in the
group to which they were originally allocated, maintain-
ing an ‘intention to treat’ analysis. Standardisation of
antibiotic regimens will limit cointervention, and con-
current use of drugs that affect antibiotic metabolism
will be documented. Any procedures that patients
undergo while in hospital and any other infections that
occur (urinary tract, Port or PICC line) will also be
documented.
Sample size consideration
The sample size calculation for the definitive trial is
based upon a between-group comparison for the
primary outcome of deep infection following long-
duration (experimental) or short-duration (control)
antibiotics. Based on our survey of Orthopaedic
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Oncologists, we will set a threshold of an absolute differ-
ence of 5% to define superiority.58 As identified by our
systematic review, infection rates after surgical excision
and endoprosthetic reconstruction of bone tumours
range from 0% to 22% with a weighted mean of 9.5%
(95% CI 8.1% to 11.0%), hence variation in the rate of
infection in the control group from 7% to 15%. Using a
baseline estimate of 10% for infection and a presumed
50% or greater reduction in the risk of deep infection,
with an ɑ of 0.05 and β of 0.20, 435 patients per study
arm will power our study at over 80% (table 2).66 67
After adjustments for potential losses to follow-up,
errors in eligibility, and study drop-outs (approximately
5% total), the total sample requirement [n_adjusted=n/
(1−0.05) where n is the calculated sample size] will be
920 patients (460 patients per arm).
Data analysis plan
The results of patient demographics and baseline charac-
teristics will be summarised using descriptive summary
measures: expressed as mean (SD) or median (minimum–
maximum) for continuous variables and number (per
cent) for categorical variables. The analysis and reporting
of the results of the clinical outcomes will follow the
CONSORT guidelines (www.consort-statement.org).
Infection rates and secondary outcomes will undergo an
intention-to-treat analysis. We will use multiple-imputation
to handle missing data.68 The infection rates in each arm
will be compared using the Cox-proportional hazards
model. We will assess the proportional hazards assumption
of the Cox model. We will use the log-rank test to assess dif-
ference between survival curves of the two groups.
Estimates of treatment effects will be reported as HR with
corresponding 95% CI and associated p values. p Values
will be reported to three decimal places with values less
than 0.001 reported as <0.001. All statistical tests will be
performed using two-sided tests at the 0.05 level of signifi-
cance. We will conduct a multiple Cox-regression model to
determine if total operative time, tumour location, chemo-
therapy regimen, diabetes, smoking or other factors are
related to infection rates. We will also conduct subgroup
analyses for infection rates within each type of tumour
(Ewing’s, Osteosarcoma, Chondrosarcoma, Giant Cell
Tumor) and tumour location (proximal femur, distal
femur and proximal tibia). Our a priori hypothesis, based
on retrospective data, is that reconstructions of the prox-
imal tibia and tumours that have been treated with neoad-
juvant or adjuvant chemotherapy (Ewing’s Sarcoma and
Osteosarcoma) will be at higher risk for deep infection
based on difficulty with soft-tissue coverage in the tibia and
the immunocompromised nature of patients on chemo-
therapy. If these subgroup analyses are underpowered, the
subgroup data will be used to generate further hypotheses
that can be tested in future trials.69 70 All analyses will be
performed using SAS V.9.2 (Cary, North Carolina, USA).
Frequency of analyses
There will be only one analysis at the end of the trial.
However, the Data Monitoring Committee (DMC) will
meet biannually to review the safety data and monitor
the progress of the trial.
Data monitoring committee
The DMC will be established at the onset of the trial to
monitor the trial and review the study biannual progress
report.69 70 The Committee members will be independ-
ent of the trial, free of conflicts with any of the investiga-
tive team and will consist of Orthopaedic Surgeons. The
terms of reference and functions are derived from the
principles established by the Data and Safety Monitoring
Boards: Lessons, Ethics, Statistics Study Group charter.
Methods and coordinating centre
This study will be coordinated by the Center for
Evidence-Based Orthopaedics (CEO) at McMaster
University in Hamilton, Ontario (figure 2). The CEO
provides faculty members within the Division of
Orthopaedic Surgery with expertise, infrastructure and
support with all aspects of clinical research project man-
agement. This includes assistance with project manage-
ment, data management, biostatistics, report preparation
Table 2 Power table for sample size calculation
Rate in control group
7% 9% 10% 13% 15%
Rate in
experimental
group
2% 269 166 138 89 72
4% 906 381 283 150 111
5% 2213 638 435 200 141
8% 10890 12208 3213 589 325
10% 1356 13495 – 1774 686
Shaded areas include between-groups differences <5% that
surgeons would not accept as different.
Figure 2 Trial structure and organization.
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and writing, and manuscript submission and tracking.
For the PARITY trial, the Program Manager at the CEO
will be responsible for overseeing the overall coordin-
ation of the study and helping to ensure that timelines
are met and that data quality is maintained. The
Research Coordinator at CEO will be responsible for the
day-to-day coordination of this study, including organisa-
tion of the committees, development of the case report
forms, training of the clinical sites, communicating with
the clinical sites, data validation and preparation of the
study reports. The Data Manager at the CEO will be
responsible for programming the participant online ran-
domisation system and the state-of-the-art data manage-
ment system with electronic data capture capabilities.
The Statistician will be responsible for conducting the
analyses of the trial data.
Potential impact of study
This study’s major strengths are numerous: The ration-
ale supporting the study design includes demonstrated
clinical uncertainly, lack of high-quality evidence and
documented strong investigator support. The high
response rate in our earlier survey underscores the cohe-
sive nature of the Orthopaedic Oncology community,
and the Methods Center at the McMaster Center for
Evidence-Based Orthopaedics possesses tremendous
expertise and experience in running large international
surgical trials.
The immediate goal of PARITY is to provide high-quality
evidence that can be used in the development of clinical
guidelines for antibiotic prophylaxis following lower-
extremity tumour excision and endoprosthetic reconstruc-
tion. More broadly, PARITY will establish a successful
network of collaboration from which further high-quality
trials in Orthopaedic Oncology will follow. Whereas sarco-
mas of the long bones are very rare tumours, multicentre
international collaboration on a large scale is necessary in
order to adequately power any high-quality trials in this
field. PARITY will mark the first such undertaking, and the
rigorous design, organisation, and execution of this trial
will set a high standard. In so doing, PARITY will lead the
development of Evidence-Based clinical guidelines and
impact on an entire field.
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